Details
Zavedos Indications
- To achieve remission in adults with acute neuromuscular leukemia (CNLL) in basic therapy, relapses or severe forms of the disease, when intravenous administration can not be applied (due to medical, psychological or social reasons);
- Progressive breast cancer after ineffective basal therapy without the use of anthracyclines in it.
Contradictions
- Patients with hypersensitivity to idarubicin or other components of the medicamnet, to other anthracyclines andanthracinidones;
- with severe lesion of kidney or liver function;
- with severe heart failure;
- with recently transferred (during the last 6 months) myocardial infarction; with severe arrhythmia;
- with persistent myelosuppression;
- with prior treatment with maximum cumulative doses of idarubicin and / or other anthracyclines and anthracene doses.
Dosage & Administration
When administered orally, Zavedos can be used in combination with other antitumor medicaments.
In adults with acute non-lymphocytic leukemia, the drug is prescribed at a rate of 30 mg / m2 once a day for 3 days as monotherapy or 15-30 mg / m2 once daily for 3 days in combination with other chemotherapeutic agents.
